

| Assessment Criteria - short version                               | Assessment Criteria - complete version                                                                                                                                                                                                                                                                                                                                                            | 1 I suggest this criterion is excluded | 2 | 3      | 4 | 5 This criterion is extremely relevant | I can't assess |        | Consensus | MEAN   | STDEV | MEDIAN | IQR | Q1     | Q3  |     | all risk tiers (A, B, and C) | only B and C | only C | I am not sure |        |    |        |    |        |    |        |   |
|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|---|--------|---|----------------------------------------|----------------|--------|-----------|--------|-------|--------|-----|--------|-----|-----|------------------------------|--------------|--------|---------------|--------|----|--------|----|--------|----|--------|---|
| Re-rated criteria                                                 |                                                                                                                                                                                                                                                                                                                                                                                                   |                                        |   |        |   |                                        |                |        |           |        |       |        |     |        |     |     |                              |              |        |               |        |    |        |    |        |    |        |   |
| 1.1.4. Possibility to give instant feedback                       | 1.1.4. The tool allows the possibility to give instant feedback to the developers (e.g., provider messaging to report technical issues or errors, inaccuracies or inconsistent workflows)                                                                                                                                                                                                         | 3,64%                                  | 2 | 5,45%  | 3 | 21,82%                                 | 12             | 41,82% | 23        | 27,27% | 15    | 0,00%  | 0   | 69,09% | 3,8 | 1,0 | 4                            | 2,0          | 3,0    | 5             |        |    |        |    |        |    |        |   |
| 1.2.2.b. Considers related health issues                          | 1.2.2.b. The tool considers multiple health issues and related ones, and sufficiently addresses them to help meet the intended purpose without overwhelming the user (i.e. consider comorbidities, and features that may improve overall quality of life, e.g. adding breathing exercises in a remote patient monitoring tool for lung cancer patients)                                           | 3,64%                                  | 2 | 3,64%  | 2 | 21,82%                                 | 12             | 30,91% | 17        | 38,18% | 21    | 1,82%  | 1   | 69,09% | 4,0 | 1,1 | 4                            | 2,0          | 3,0    | 5             |        |    |        |    |        |    |        |   |
| 1.3.1.c. Sufficient information                                   | 1.3.1.c. There is sufficient information throughout the tool without any omissions, over-explanations, or irrelevant data                                                                                                                                                                                                                                                                         | 1,82%                                  | 1 | 5,45%  | 3 | 10,91%                                 | 6              | 40,00% | 22        | 38,18% | 21    | 3,64%  | 2   | 78,18% | 4,1 | 1,0 | 4                            | 1,0          | 4,0    | 5             |        |    |        |    |        |    |        |   |
| 1.4.2.b. Allows different platforms                               | 1.4.2.b. The tool allows the users to move across different platforms to allow portability of the tool while retaining their data (e.g. mobile app vs web app, iOS vs Android, older smartphones)                                                                                                                                                                                                 | 0,00%                                  | 0 | 7,27%  | 4 | 20,00%                                 | 11             | 20,00% | 11        | 50,91% | 28    | 1,82%  | 1   | 70,91% | 4,2 | 1,0 | 5                            | 2,0          | 3,0    | 5             |        |    |        |    |        |    |        |   |
| 1.4.3. Can be used in real time                                   | 1.4.3. The tool can be used in real time (i.e. real-time data tracking), e.g. if the user is experiencing a health issue, reducing waits and sometimes harmful delays for both those who receive and those who give care                                                                                                                                                                          | 7,27%                                  | 4 | 3,64%  | 2 | 21,82%                                 | 12             | 27,27% | 15        | 36,36% | 20    | 3,64%  | 2   | 63,63% | 3,8 | 1,2 | 4                            | 2,0          | 3,0    | 5             |        |    |        |    |        |    |        |   |
| 2.1.1.a. High quality interactive features                        | 2.1.1.a. The tool includes high quality interactive features (enables user input and reaction) and is presented in an engaging way (e.g., contains the right mix of video/audio/text/graphics)                                                                                                                                                                                                    | 1,82%                                  | 1 | 1,82%  | 1 | 21,82%                                 | 12             | 41,82% | 23        | 32,73% | 18    | 0,00%  | 0   | 74,55% | 4,0 | 0,9 | 4                            | 1,5          | 3,5    | 5             |        |    |        |    |        |    |        |   |
| 2.1.1.b. Customisability                                          | 2.1.1.b. The tool is customisable and allows the user to control all the necessary settings and features (e.g., notifications, alerts, sounds, colours, and fonts) except for the features that form an essential part of an intervention (e.g. the tool allows the patients to customise the time of a certain reminder according to their daily routine but doesn't allow them to remove it)    | 1,82%                                  | 1 | 5,45%  | 3 | 21,82%                                 | 12             | 38,18% | 21        | 30,91% | 17    | 1,82%  | 1   | 69,09% | 3,9 | 1,0 | 4                            | 2,0          | 3,0    | 5             |        |    |        |    |        |    |        |   |
| 2.1.2.a. Persuasiveness and behavioural change                    | 2.1.2.a. The tool is persuasive and aims at understanding what influences people's behaviour and decision making, and then uses this information to design compelling user interactions by offering relevant and customisable therapeutic activities and encouraging users to complete them (e.g. through incentivisation, gamification etc.) in a way that balances engagement vs tool addiction | 0,00%                                  | 0 | 7,27%  | 4 | 34,55%                                 | 19             | 30,91% | 17        | 25,45% | 14    | 1,82%  | 1   | 56,36% | 3,8 | 0,9 | 4                            | 1,8          | 3,0    | 4,75          |        |    |        |    |        |    |        |   |
| 2.3.1. Visible users' reviews                                     | 2.3.1. The tool's visible and verified users' reviews and ratings are favourable (e.g. a star rating above 4/5 stars in the app store, or the Net Promoter Score - NPS). Using users' perceived value through users' reviews and ratings as a proxy for quality, usefulness, or acceptability and popularity                                                                                      | 5,45%                                  | 3 | 16,36% | 9 | 34,55%                                 | 19             | 34,55% | 19        | 9,09%  | 5     | 0,00%  | 0   | 43,64% | 3,3 | 1,0 | 3                            | 1,0          | 3,0    | 4             |        |    |        |    |        |    |        |   |
| 2.4.1.a. Verified and endorsed by a health authority              | 2.4.1.a. The tool has been verified, given a good review, or endorsed by a legitimate/reliable source such as a health organisation or health authority (e.g. APA; FDA in the US; NIH; NHS in the UK; NICE in the UK) or recommended by trusted Healthcare Professionals                                                                                                                          | 0,00%                                  | 0 | 3,64%  | 2 | 10,91%                                 | 6              | 27,27% | 15        | 56,36% | 31    | 1,82%  | 1   | 83,63% | 4,4 | 0,8 | 5                            | 1,0          | 4,0    | 5             |        |    |        |    |        |    |        |   |
| 2.4.1.b. Possibilities for peer support                           | 2.4.1.b. The tool provides possibilities for peer support and/or social networking (e.g. anecdotal evidence - a space to share experiences like patient forums, groups etc.) and/or supported by patient organisations or advisory groups                                                                                                                                                         | 3,64%                                  | 2 | 16,36% | 9 | 27,27%                                 | 15             | 29,09% | 16        | 23,64% | 13    | 0,00%  | 0   | 52,73% | 3,5 | 1,1 | 4                            | 1,0          | 3,0    | 4             |        |    |        |    |        |    |        |   |
| 3.1.3. Implementation and user base                               | 3.1.3. The tool is implemented and utilised within the target health system under usual care OR a large group of clinicians officially refers patients to utilise it (this can be checked by looking at the unique monthly users and their percentage in relation to the target population in the target health system/market). The size of the target population needs to be evidence based      | 1,82%                                  | 1 | 10,91% | 6 | 21,82%                                 | 12             | 34,55% | 19        | 23,64% | 13    | 7,27%  | 4   | 58,19% | 3,7 | 1,0 | 4                            | 1,5          | 3,0    | 4,5           |        |    |        |    |        |    |        |   |
| 3.2.1. Feasibility of implementation planning                     | 3.2.1. Assesses the extent to which the tool can be implemented as intended (i.e., feasibility of implementing the tool at a pre-determined date and time). This can be checked by looking at how long it takes, on average, from the contractual agreement until the tool is fully up and running in a healthcare organisation                                                                   | 5,45%                                  | 3 | 10,91% | 6 | 36,36%                                 | 20             | 30,91% | 17        | 10,91% | 6     | 5,45%  | 3   | 41,82% | 3,3 | 1,0 | 3                            | 1,0          | 3,0    | 4             |        |    |        |    |        |    |        |   |
| 3.3.1. Favourable pre-conditions                                  | 3.3.1. How favourable are the pre-conditions (strategic, political, and environmental contexts) that influence the scaling up of the eHealth tool. For example, the tool's suitability to the socioeconomic context in question, considerations of foreign languages that the tool needs to support, literacy level, and the local regulatory environment such as reimbursement                   | 0,00%                                  | 0 | 10,91% | 6 | 14,55%                                 | 8              | 45,45% | 25        | 27,27% | 15    | 1,82%  | 1   | 72,72% | 3,9 | 0,9 | 4                            | 1,8          | 3,3    | 5             |        |    |        |    |        |    |        |   |
| 3.4.1.a. Provider details availability                            | 3.4.1.a. Contact details of the tool's provider are available, easy to find, and include office address, email, and team members details                                                                                                                                                                                                                                                          | 3,64%                                  | 2 | 10,91% | 6 | 25,45%                                 | 14             | 32,73% | 18        | 27,27% | 15    | 0,00%  | 0   | 60,00% | 3,7 | 1,1 | 4                            | 2,0          | 3,0    | 5             |        |    |        |    |        |    |        |   |
| 3.4.1.b. Credentials of those involved in development and funding | 3.4.1.b. Availability of information and credentials of the individuals and organisations involved in the development and funding of the tool (transparency on the involvement of any parties that may lead to conflict of interest, e.g. commercial sponsors and partners, financial disclosure)                                                                                                 | 0,00%                                  | 0 | 12,73% | 7 | 25,45%                                 | 14             | 32,73% | 18        | 29,09% | 16    | 0,00%  | 0   | 61,82% | 3,8 | 1,0 | 4                            | 2,0          | 3,0    | 5             |        |    |        |    |        |    |        |   |
| 3.4.4. Provider eHealth or healthcare experience                  | 3.4.4. The tool's provider and/or its core team members have specific experience in the eHealth field OR academic institution (e.g., university) OR health care system (or large health providers' organisation). E.g. an experienced medical director that oversees the algorithms / contents / features of the tool                                                                             | 1,82%                                  | 1 | 7,27%  | 4 | 18,18%                                 | 10             | 32,73% | 18        | 40,00% | 22    | 0,00%  | 0   | 72,73% | 4,0 | 1,0 | 4                            | 2,0          | 3,0    | 5             |        |    |        |    |        |    |        |   |
| Newly added criteria                                              |                                                                                                                                                                                                                                                                                                                                                                                                   |                                        |   |        |   |                                        |                |        |           |        |       |        |     |        |     |     |                              |              |        |               |        |    |        |    |        |    |        |   |
| 1.3.1.d. Content reviewed by patients                             | 1.3.1.d. The content has been reviewed by patients to ensure readability and acceptability                                                                                                                                                                                                                                                                                                        | 0,00%                                  | 0 | 1,82%  | 1 | 5,45%                                  | 3              | 32,73% | 18        | 60,00% | 33    | 0,00%  | 0   | 92,73% | 4,5 | 0,7 | 5                            | 1,0          | 4,0    | 5             | 58,18% | 32 | 32,73% | 18 | 5,45%  | 3  | 3,64%  | 2 |
| 1.4.1.d. Enables easy data deletion                               | 1.4.1.d. The tool explicitly and easily enables users to delete their data                                                                                                                                                                                                                                                                                                                        | 1,82%                                  | 1 | 1,82%  | 1 | 14,55%                                 | 8              | 25,45% | 14        | 50,91% | 28    | 5,45%  | 3   | 76,36% | 4,3 | 0,9 | 5                            | 1,0          | 4,0    | 5             | 56,36% | 31 | 30,91% | 17 | 3,64%  | 2  | 9,09%  | 5 |
| 1.4.3.b. Reliable and available at all times                      | 1.4.3.b. The tool is reliable and available at all times and can handle high levels of traffic and usage, with backup and recovery measures in case of downtime or system failures (e.g. enabling offline functionality, functioning during energy interruption or under difficult environmental conditions)                                                                                      | 1,82%                                  | 1 | 3,64%  | 2 | 10,91%                                 | 6              | 29,09% | 16        | 54,55% | 30    | 0,00%  | 0   | 83,64% | 4,3 | 0,9 | 5                            | 1,0          | 4,0    | 5             | 47,27% | 26 | 21,82% | 12 | 29,09% | 16 | 1,82%  | 1 |
| 1.4.4. Compliantly allows data sharing                            | 1.4.4. The tool compliantly allows for data sharing and segregation for research use (including data analytics and reporting, quality improvement initiatives, and clinical trials)                                                                                                                                                                                                               | 0,00%                                  | 0 | 3,64%  | 2 | 16,36%                                 | 9              | 34,55% | 19        | 45,45% | 25    | 0,00%  | 0   | 80,00% | 4,2 | 0,9 | 4                            | 1,0          | 4,0    | 5             | 52,73% | 29 | 32,73% | 18 | 10,91% | 6  | 3,64%  | 2 |
| 1.4.5. Metadata definition, findability, and retrievability       | 1.4.5. Data findability and retrievability: Metadata definition (including e.g. units used, reference to controlled vocabularies, ontologies) and the ability for users to retrieve data with the same granularity specified by the metadata (up to and including raw data sets)                                                                                                                  | 3,64%                                  | 2 | 9,09%  | 5 | 25,45%                                 | 14             | 27,27% | 15        | 23,64% | 13    | 10,91% | 6   | 50,91% | 3,7 | 1,1 | 4                            | 2,0          | 3,0    | 5             | 52,73% | 29 | 27,27% | 15 | 5,45%  | 3  | 14,55% | 8 |
| 1.5.1.c. Usability in the intended clinical setting               | 1.5.1.c. The tool is usable and accessible in the intended clinical setting (e.g. if it is used by HCPs in a clinical setting, can they use it while wearing gloves, e.g. are buttons big enough and separated)                                                                                                                                                                                   | 0,00%                                  | 0 | 7,27%  | 4 | 18,18%                                 | 10             | 29,09% | 16        | 41,82% | 23    | 3,64%  | 2   | 70,91% | 4,1 | 1,0 | 4                            | 2,0          | 3,0    | 5             | 49,09% | 27 | 21,82% | 12 | 18,18% | 10 | 10,91% | 6 |
| 2.1.3.c. Affordability and business model transparency            | 2.1.3.c. Affordability of the tool taking into account the local socioeconomic context, and clarity on who pays and how do they pay                                                                                                                                                                                                                                                               | 3,64%                                  | 2 | 1,82%  | 1 | 18,18%                                 | 10             | 27,27% | 15        | 49,09% | 27    | 0,00%  | 0   | 76,36% | 4,2 | 1,0 | 4                            | 1,0          | 4,0    | 5             | 70,91% | 39 | 18,18% | 10 | 5,45%  | 3  | 5,45%  |   |

|                                                                 |  |                                                                                                                                                                                                                                                                                                                                                                              |   |       |   |        |    |        |    |        |    |       |   |        |     |     |   |     |     |   |        |    |        |    |        |   |        |   |
|-----------------------------------------------------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|-------|---|--------|----|--------|----|--------|----|-------|---|--------|-----|-----|---|-----|-----|---|--------|----|--------|----|--------|---|--------|---|
|                                                                 |  | 2.2.3.d. The tool differentiates between clinical and technical feedback and clearly channels clinical feedback that may pose a health risk through the proper channels (e.g. advising the patient to call their care team, go to the ER....) and reviews them for vigilance and post-market surveillance purposes and, where relevant, notify them to competent authorities |   |       |   |        |    |        |    |        |    |       |   |        |     |     |   |     |     |   |        |    |        |    |        |   |        |   |
| 2.2.3.d. Differentiates between clinical and technical feedback |  | 3,64%                                                                                                                                                                                                                                                                                                                                                                        | 2 | 0,00% | 0 | 9,09%  | 5  | 34,55% | 19 | 52,73% | 29 | 0,00% | 0 | 87,28% | 4,3 | 0,9 | 5 | 1,0 | 4,0 | 5 | 50,91% | 28 | 34,55% | 19 | 12,73% | 7 | 1,82%  | 1 |
| 3.4.5. Availability of phase-out scenarios                      |  | 3.4.5. Availability of phase-out scenarios, if the tool's provider stops producing/maintaining the tool                                                                                                                                                                                                                                                                      |   |       |   |        |    |        |    |        |    |       |   |        |     |     |   |     |     |   |        |    |        |    |        |   |        |   |
|                                                                 |  | 1,82%                                                                                                                                                                                                                                                                                                                                                                        | 1 | 5,45% | 3 | 23,64% | 13 | 29,09% | 16 | 32,73% | 18 | 7,27% | 4 | 61,82% | 3,9 | 1,0 | 4 | 2,0 | 3,0 | 5 | 49,09% | 27 | 27,27% | 15 | 9,09%  | 5 | 14,55% | 8 |